BioCentury
ARTICLE | Clinical News

Amgevita, Solymbic regulatory update

February 3, 2017 12:01 AM UTC

EMA's CHMP recommended approval of ABP 501 to treat autoimmune diseases under 2 names: Amgevita and Solymbic. Amgen is seeking approval of the biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:AB...

BCIQ Company Profiles

Amgen Inc.